The Pro Medicus Limited (ASX:PME) share price is up 23% in 2021 but could still go even higher from here according to Goldman Sachs…
The post The Pro Medicus (ASX:PME) share price is up 23% in 2021: Can it go higher? appeared first on The Motley Fool Australia. –
In afternoon trade, the health imaging company’s shares are down 0.5% to $43.11.
However, despite this, the Pro Medicus share price is still up a sizeable 23% since the start of the year.
Why is the Pro Medicus share price up 23% in 2021?
Investors have been fighting to get hold of the company’s shares this year thanks to a solid half year result, a series of major new contract wins, and a bullish broker note.
In respect to its first half performance, for the six months ended 31 December, Pro Medicus reported a 7.8% increase in revenue to $31.6 million and a 29% (constant currency) increase in underlying profit before tax to $19.7 million.
Positively, since the end of the half, the company has signed two major new contracts. One was a $40 million 7-year deal with Intermountain Health and the other was a $31 million 7-year deal with a large University Health System.
Can Pro Medicus shares go higher?
The good news for investors is that one leading broker believes the Pro Medicus share price can still go higher from here.
That broker is Goldman Sachs. Last month its analysts upgraded the company’s shares to a buy rating with a $53.80 price target.
Based on the current Pro Medicus share price, this implies potential upside of 25% over the next 12 months.
Why is Goldman so positive?
Goldman Sachs has been impressed with the way the company continues to win large contracts despite the difficult operating environment. The broker feels this leaves it well-positioned to grow its earnings at a rapid rate over the coming years.
And although the Pro Medicus share price trades at a premium to the market average, Goldman believes its growth profile justifies this.
It commented: “Whilst not cheap in absolute terms, our new estimates imply a +42% EBITDA CAGR (FY20-23E). In the context of ASX Healthcare, which trades at a ‘multiple to growth’ ratio of 2.9x, we do not see PME’s ratio of 1.4x as demanding, particularly given its position as a technology leader in a market we believe is set for further technology upgrades, and a recurrent revenue model with inherent upside. We upgrade to Buy.”
So, while Pro Medicus shares has been on fire in 2021, it appears as though they may still have further to run in the coming months.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of February 15th 2021
- Is it ok to buy ASX 200 shares at a 52-week high?
- ASX 200 rises, Afterpay sinks, Vocus jumps
- 5 ASX shares to buy in a market crash
- 2 strong ASX healthcare shares to buy this month
- Is it time to buy these 2 hot ASX healthcare shares?
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends Pro Medicus Ltd. The Motley Fool Australia has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.